Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38815015.
- Also identified by DOI 10.1126/science.add6260 and PMC identifier 11827694.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Abnormal calcium signaling is a central pathological component of Alzheimer's disease (AD). Here, we describe the identification of a class of compounds called ReS19-T, which are able to restore calcium homeostasis in cell-based models of tau pathology. Aberrant tau accumulation leads to uncontrolled activation of store-operated calcium channels (SOCCs) by remodeling septin filaments at the cell cortex. Binding of ReS19-T to septins restores filament assembly in the disease state and restrains calcium entry through SOCCs. In amyloid-β and tau-driven mouse models of disease, ReS19-T agents restored synaptic plasticity, normalized brain network activity, and attenuated the development of both amyloid-β and tau pathology. Our findings identify the septin cytoskeleton as a potential therapeutic target for the development of disease-modifying AD treatments.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Calcium
- Homeostasis
- Neuroprotective Agents
- Septins
- tau Proteins